Skip to content
x.com· @ · X·· 2026-04-21Score60
Body

Novel pan-RAF/MEK molecular glue NST-628 shows promise at #AACR26:

38% ORR & 85% DCR in pretreated NRAS/BRAF class II/III melanoma
Demonstrates CNS activity
Manageable safety profile (predominantly G1-2 AEs)

https://t.co/YuZle4FAHu

Heat 1 · 1 like · 0 replies · 0 reposts

Conference abstracts
CT129matched by 代号 NST-628
Preliminary results from a Phase 1a/b dose-escalation and expansion trial of the pan-RAF-MEK molecular glue NST-628 in patients (pts) with advanced or refractory RAF, KRAS, and NRAS-mutant solid tumors

Ahmad A. Tarhini, Monica Chen, Jia Liu, Varun Monga, Victoria Atkinson, Sarina A. Piha-Paul, Bartosz Chmielowski, Benjamin Herzberg, Charlotte Lemech, Prachi Bhave, Ganessan Kichenadasse, Gerald Falchook, Janice Mehnert, Andrae Vandross, Mohamad Salkeni, Meredith McKean, David Wages, Ann Marie Kennedy, Meagan B. Ryan, John Clark, Abdulaziz Nanah, Michael J. Fossler, Philip Komarnitsky, Igor Puzanov

Read the abstract →

Source: x.com · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org